JP6247697B2 - スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用 - Google Patents

スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用 Download PDF

Info

Publication number
JP6247697B2
JP6247697B2 JP2015542108A JP2015542108A JP6247697B2 JP 6247697 B2 JP6247697 B2 JP 6247697B2 JP 2015542108 A JP2015542108 A JP 2015542108A JP 2015542108 A JP2015542108 A JP 2015542108A JP 6247697 B2 JP6247697 B2 JP 6247697B2
Authority
JP
Japan
Prior art keywords
group
compound
optionally substituted
methyl
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015542108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510719A (ja
JP2016510719A5 (enExample
Inventor
静夫 河西
静夫 河西
正樹 荻野
正樹 荻野
亮 溝尻
亮 溝尻
健 山▲崎▼
健 山▲崎▼
英喜 廣瀬
英喜 廣瀬
信幸 ▲高▼倉
信幸 ▲高▼倉
山下　徹
徹 山下
幸恵 森本
幸恵 森本
崇 中畑
崇 中畑
朝人 喜名
朝人 喜名
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to JP2015542108A priority Critical patent/JP6247697B2/ja
Publication of JP2016510719A publication Critical patent/JP2016510719A/ja
Publication of JP2016510719A5 publication Critical patent/JP2016510719A5/ja
Application granted granted Critical
Publication of JP6247697B2 publication Critical patent/JP6247697B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015542108A 2013-03-14 2014-03-13 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用 Expired - Fee Related JP6247697B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015542108A JP6247697B2 (ja) 2013-03-14 2014-03-13 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013052482 2013-03-14
JP2013052482 2013-03-14
JP2015542108A JP6247697B2 (ja) 2013-03-14 2014-03-13 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
PCT/JP2014/058144 WO2014142363A1 (en) 2013-03-14 2014-03-13 Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists

Publications (3)

Publication Number Publication Date
JP2016510719A JP2016510719A (ja) 2016-04-11
JP2016510719A5 JP2016510719A5 (enExample) 2017-02-23
JP6247697B2 true JP6247697B2 (ja) 2017-12-13

Family

ID=50478533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542108A Expired - Fee Related JP6247697B2 (ja) 2013-03-14 2014-03-13 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用

Country Status (5)

Country Link
US (1) US9605000B2 (enExample)
EP (1) EP2970331B1 (enExample)
JP (1) JP6247697B2 (enExample)
ES (1) ES2629729T3 (enExample)
WO (1) WO2014142363A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2907820B1 (ja) 1998-06-19 1999-06-21 有限会社アシスト 樹脂フィルム等の成形方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
RS58321B1 (sr) 2013-10-29 2019-03-29 Takeda Pharmaceuticals Co Heterociklično jedinjenje
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
US10879420B2 (en) 2018-07-09 2020-12-29 University Of Iowa Research Foundation Cascaded superlattice LED system
CN116354961B (zh) * 2021-12-27 2025-07-25 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途
WO2024204277A1 (ja) 2023-03-27 2024-10-03 株式会社スコヒアファーマ 成長ホルモン分泌促進剤

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
EP1556032A1 (en) 2002-11-01 2005-07-27 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
CA2551610A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
UA97257C2 (en) 2006-10-19 2012-01-25 Такеда Фармасьютикал Компани Лимитед Indole derivatives
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
MX2009008103A (es) 2007-02-09 2009-08-18 Takeda Pharmaceutical Compuestos anulares fusionados como agonistas parciales de prar-gamma.
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2318388A2 (en) * 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
WO2010129729A1 (en) * 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
CA2799414A1 (en) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Spiro isoxazoline compounds as sstr5 antagonists
US8742110B2 (en) * 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
JO3442B1 (ar) * 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
RS58321B1 (sr) * 2013-10-29 2019-03-29 Takeda Pharmaceuticals Co Heterociklično jedinjenje

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2907820B1 (ja) 1998-06-19 1999-06-21 有限会社アシスト 樹脂フィルム等の成形方法

Also Published As

Publication number Publication date
US9605000B2 (en) 2017-03-28
WO2014142363A1 (en) 2014-09-18
JP2016510719A (ja) 2016-04-11
US20160060273A1 (en) 2016-03-03
EP2970331A1 (en) 2016-01-20
ES2629729T3 (es) 2017-08-14
EP2970331B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
JP6458054B2 (ja) 複素環化合物
DK3031799T3 (en) AROMATIC CONNECTION
JP6411520B2 (ja) 複素環化合物
TWI749661B (zh) 雜環化合物
WO2018181847A1 (ja) 芳香環化合物
US9605000B2 (en) Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
US9975903B2 (en) Condensed heterocyclic compound
JP6450755B2 (ja) 複素環化合物
WO2016121782A1 (ja) スルホンアミド化合物
WO2016158788A1 (ja) 縮合複素環化合物
JPWO2016159049A1 (ja) 単環式化合物
HK1241884B (en) Heteroaryl compounds for the treatment of ophthalmic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171117

R150 Certificate of patent or registration of utility model

Ref document number: 6247697

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees